Authors : Vishal Kulkarni, Shahriar Roushani, Vaibhav Rajhans, Gulsitan Sayeda
DOI : 10.18231/j.ijmmtd.2020.006
Volume : 6
Issue : 1
Year : 2020
Page No : 28-32
Introduction: India has the highest burden of both tuberculosis (TB) and Multidrug Resistant tuberculosis
(MDR-TB), based on estimates reported in Global TB Report 2016. Conventional diagnostic techniques are
less sensitive & time consuming. The Xpert MTB/RIF Assay has the capacity to revolutionize the diagnosis
of TB because of its speed, sensitivity and specificity. The objectives of our study are to determine the rate
of positivity of Mycobacterial tuberculosis complex among the different clinical specimen and to know the
rate of Rifampicin resistance among these specimens by using Xpert MTB/RIF Assay.
Materials and Methods: The study was conducted in Department of Microbiology, Rural Medical
College, (PIMS), Loni. Clinical Samples from suspected TB cases were treated according to Manufacturer’s
Instructions & Standard operating procedure.
Result: A total of 1528 Samples received during the study period out of which 267 (17.47%) were positive
for Mycobacterium tuberculosis complex (MTBC) and 15 (0.98%) were rifampicin resistant. Maximum
positivity was noted in age group 21-30 years. Out of total 126 extrapulmonary specimens, 10 were positive
for MTBC. Also out of 273 HIV infected cases 16 samples were positive for MTBC while 1 was Rifampicin
resistant.
Conclusion: Accurate early diagnosis and treatment of TB has the potential to reduce morbidity and
mortality associated with MDR TB. Xpert MTB /RIF assay has brought revolution in the earliest diagnosis
(Turn around time-2.5hrs) compared to culture (which takes weeks) with simultaneous drug susceptibility
testing.
Keywords: Multidrug Resistant Tuberculosis, Rifampicin Resistance, CBNAAT.